Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure.

Mubeen Khan Mohammed Abdul, Heather S Snyder, Mythili Chunduru, Susan M K Lee, Sanjaya K Satapathy
{"title":"Hepatitis C Virus in the Elderly in the Direct-Acting Antiviral Era: from Diagnosis to Cure.","authors":"Mubeen Khan Mohammed Abdul,&nbsp;Heather S Snyder,&nbsp;Mythili Chunduru,&nbsp;Susan M K Lee,&nbsp;Sanjaya K Satapathy","doi":"10.1007/s40506-020-00231-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the advent of second-generation DAA in 2013, numerous robust real-world experiences highlighting the efficacy and safety of DAA in the elderly have been published. This review article summarizes the cascade of care for hepatitis C from diagnosis to cure from an evidence-based perspective of the aging population.</p><p><strong>Recent finding: </strong>In a large study from the Veterans Affairs Healthcare System, the overall sustained virologic response (SVR) of 15,884 patients treated with DAA regimens was 91.2%. These newer therapies remained highly effective in the subset of patients aged 65 years and older with SVR rates above 90%. A Spanish National Registry reported outcomes in patients ≥ 65 years old treated for HCV with oral DAA regimens over a 2-year period. The overall SVR was 94% in the study of 1252 subjects.</p><p><strong>Summary: </strong>Current real-world data imply DAA treatment regimens remain highly effective and safe in elderly patients when compared to the general population.</p>","PeriodicalId":72759,"journal":{"name":"Current treatment options in infectious diseases","volume":"12 3","pages":"296-309"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40506-020-00231-8","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current treatment options in infectious diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40506-020-00231-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/8/11 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Purpose of review: Hepatitis C (HCV) is the most common cause of viral hepatitis in elderly individuals. This patient population previously experienced suboptimal outcomes with interferon-based regimens. Unfortunately, patients aged 65 years and older were underrepresented in phase 2 and 3 clinical trials with newer direct acting antiviral (DAA) therapies. Since the advent of second-generation DAA in 2013, numerous robust real-world experiences highlighting the efficacy and safety of DAA in the elderly have been published. This review article summarizes the cascade of care for hepatitis C from diagnosis to cure from an evidence-based perspective of the aging population.

Recent finding: In a large study from the Veterans Affairs Healthcare System, the overall sustained virologic response (SVR) of 15,884 patients treated with DAA regimens was 91.2%. These newer therapies remained highly effective in the subset of patients aged 65 years and older with SVR rates above 90%. A Spanish National Registry reported outcomes in patients ≥ 65 years old treated for HCV with oral DAA regimens over a 2-year period. The overall SVR was 94% in the study of 1252 subjects.

Summary: Current real-world data imply DAA treatment regimens remain highly effective and safe in elderly patients when compared to the general population.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
直接抗病毒时代老年人丙型肝炎病毒:从诊断到治疗。
综述目的:丙型肝炎(HCV)是老年人病毒性肝炎最常见的病因。这些患者以前使用干扰素治疗方案的结果不理想。不幸的是,65岁及以上的患者在使用新的直接作用抗病毒(DAA)疗法的2期和3期临床试验中代表性不足。自2013年第二代DAA问世以来,已经发表了许多强有力的现实经验,强调了DAA在老年人中的有效性和安全性。这篇综述文章总结了丙型肝炎从诊断到治愈的护理级联从循证视角的老龄化人口。最近的发现:在一项来自退伍军人事务医疗保健系统的大型研究中,15,884名接受DAA方案治疗的患者的总体持续病毒学反应(SVR)为91.2%。这些新疗法在65岁及以上SVR率超过90%的患者亚群中仍然非常有效。西班牙国家登记处报告了≥65岁的HCV患者口服DAA方案治疗2年的结果。1252名受试者的总体SVR为94%。总结:目前的实际数据表明,与一般人群相比,DAA治疗方案在老年患者中仍然非常有效和安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Antiviral Nanomedicine-Based Approaches against Epstein-Barr Virus Infection Adenovirus Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation Malaria Therapeutic Paradigm: An Evolution Towards Commercial Drug Delivery Technology Molecular Imaging Techniques in the Diagnosis and Monitoring of Infectious Diseases Art of the Transplant Infectious Diseases Consult: Storytelling and Science
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1